Latest kidney cancer Stories
Small kidney tumors have an aggressive potential and should be treated, according to a the results of a large multi-center study presented at the 28th Annual EAU Congress in Milan. "Many clinicians regard small renal cell cancer as having a benign biologic behavior and non-operative surveillance protocols are often being used in patients with small renal tumors," write the authors in the findings. "The aim of this large retrospective multi-center study was to evaluate the prevalence of...
PHILADELPHIA and REHOVOT, Israel, March 12, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that Ken Berlin, President and Chief Executive Officer of the Company, will present a corporate overview at the 25th Annual Roth Conference taking place from March 17-20, 2013 at the Ritz-Carlton Laguna Niguel in California. Mr. Berlin's presentation will take place on Tuesday, March 19(th) at...
A new immunoassay that tests for the presence of three biomarkers appears to be a valid screening method for the early detection of malignant kidney cancer, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. "Renal cell carcinoma, a malignant tumor arising from the kidney, is one of the most difficult forms of cancer to detect and treat properly because it remains silent until disseminating to other...
New Study Points to Advantages of Robotic Surgery WASHINGTON, March 11, 2013 /PRNewswire-USNewswire/ -- For patients with kidney tumors, a new study shows the health and economic advantages to removing just the tumor as opposed to the entire kidney. Robotic surgery, including the daVinci Surgical System and Firefly fluorescence imaging that lights up kidney tumors, are among the latest techniques to make this possible. The retrospective study conducted by MedStar Georgetown...
PHILADELPHIA and REHOVOT, Israel, Feb. 7, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that data from a study demonstrating the ability of microRNA expression to serve as a biomarker to predict the progression of bladder urothelial carcinoma were published online in the British Journal of Urology International, in an article entitled, "Predicting progression of bladder...
Study shows drug can shrink tumors and save kidneys Thousands of individuals have had kidneys removed unnecessarily because doctors misdiagnosed their disease. A new, international study published in The Lancet indicates that approximately one of every five individuals with kidney tumors common in patients with tuberous sclerosis complex (TSC), a genetic disorder, has had a kidney removed. Moreover, 40 percent had some kind of surgical procedure performed. Proper diagnosis could have...
EAST HANOVER, N.J., Jan. 10, 2013 /PRNewswire/ -- Data published today in The Lancet showed that patients on Afinitor(®) (everolimus) tablets with non-cancerous kidney tumors known as renal angiomyolipomas associated with tuberous sclerosis complex (TSC) experienced a significant reduction in tumor size and the absence of tumor progression(1). Additionally, a recent issue of The Lancet featured results from a separate everolimus trial demonstrating a reduction in the size of...
PHILADELPHIA and REHOVOT, Israel, Jan. 9, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that data from a study assessing the differences between cancer of unknown primary (CUP) and metastatic solid tumors of known primary metastases (KPM) by profiling microRNA expression were recently published in Clinical Experimental Metastasis, in an article entitled "Global microRNA profiling in...
PHILADELPHIA and REHOVOT, Israel, Jan. 4, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that Kenneth A. Berlin, President and CEO, is scheduled to present a corporate overview at Sidoti & Company's 2013 Micro-Cap Conference on Monday, January 7, 2013 at The Grand Hyatt Hotel in New York City. The Rosetta Genomics presentation is scheduled for 9:20 a.m. Eastern Time. The...
LOS ANGELES, Jan. 3, 2013 /PRNewswire/ -- Kidney Cancer Association, Urology Care Foundation, and Conquer Cancer Foundation welcome grant requests supported by donations from ShoeDazzle and celebrity Denise Richards. The world's largest charity dedicated exclusively to the eradication of death and suffering from renal cancers, the Kidney Cancer Association (KCA), announces the availability of funds for research projects. "We partner with the Conquer Cancer Foundation and...
